Novastan Multidos (Argatroban Monohydrate)

Argatroban, the active ingredient in Novastan Multidos, is a Direct thrombin inhibitor presented as an unknown/Injectable solution for intravenous use. It is employed to anticoagulate patients with heparin‑induced thrombocytopenia and during percutaneous coronary intervention procedures. GNH USA supplies Novastan Multidos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Novastan Multidos, a direct thrombin inhibitor, is used in clinical settings where anticoagulation is required without heparin. - Heparin‑induced thrombocytopenia (HIT): provides effective anticoagulation when heparin is contraindicated. - Percutaneous coronary intervention (PCI): maintains anticoagulation throughout the interventional procedure. - Cardiac surgery requiring anticoagulation: supports anticoagulation during cardiopulmonary bypass and related surgical contexts.

Common Side Effects: - Bleeding: minor to moderate hemorrhage at infusion sites or mucosal surfaces. - Thrombocytopenia: reduction in platelet count observed during therapy. - Elevated liver enzymes: transient increases in ALT or AST. - Nausea or headache: mild gastrointestinal or neurologic discomfort. - Fever: low‑grade temperature elevation.

Serious or Rare Side Effects: - Major bleeding: life‑threatening hemorrhage requiring medical intervention. - Hepatic failure: severe liver dysfunction in susceptible patients. - Anaphylaxis: acute hypersensitivity reaction with respiratory compromise. - Hemolysis: destruction of red blood cells leading to anemia. - Thrombotic events: paradoxical clot formation in rare cases.

Novastan Multidos requires careful clinical monitoring to ensure safe use. - Coagulation monitoring: regularly assess activated clotting time (ACT) or aPTT. - Liver function: evaluate hepatic enzymes before and during therapy. - Dose adjustment: reduce dose in patients with moderate to severe hepatic impairment. - Active bleeding: avoid use in patients with uncontrolled hemorrhage. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Argatroban may interact with other agents that affect hemostasis or hepatic metabolism. Major Interactions (Avoid): - Concurrent anticoagulants (e.g., warfarin, heparin): markedly increased bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): elevate argatroban plasma levels. - Antiplatelet drugs (e.g., aspirin, clopidogrel) at full dose: synergistic hemorrhagic effect.

Moderate Interactions (Monitor Closely): - Mild CYP3A4 inhibitors (e.g., fluconazole): may modestly raise drug concentration. - NSAIDs or other non‑steroidal anti‑inflammatories: increase minor bleeding tendency. - Fibrinolytic agents (e.g., alteplase): additive anticoagulant effect requiring close observation.